• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

超声心动图检查期间低应激剂量的阿巴美明诱发心肌缺血的充分性。国际阿巴美明研究组。

Adequacy of low-stress arbutamine to provoke myocardial ischemia during echocardiography. International Arbutamine Study Group.

作者信息

Bach D S, Armstrong W F

机构信息

Department of Internal Medicine, University of Michigan, Ann Arbor, USA.

出版信息

Am J Cardiol. 1995 Aug 1;76(4):259-62. doi: 10.1016/s0002-9149(99)80077-0.

DOI:10.1016/s0002-9149(99)80077-0
PMID:7618620
Abstract

Arbutamine is a new, potent, short-acting synthetic catecholamine developed specifically for use as a cardiac stress agent. Previous reports on the accuracy of arbutamine for the detection of coronary artery disease have relied on heart rate (HR) increases similar to those seen at peak exercise. This study was undertaken to test the potential to provoke ischemic wall motion abnormalities on echocardiography using arbutamine at a HR below that associated with peak exercise. One hundred forty-six patients with coronary artery disease underwent computerized closed-loop stress testing with arbutamine; 120 (82%) had echocardiographic images adequate for analysis at baseline, low stress (20 beats/min above baseline), and peak stress (target of 85% age-predicted peak HR). Ejection fraction increased from 59 +/- 10% at baseline to 72 +/- 12% at low stress, and remained stable at 72 +/- 14% at peak stress. Of 88 patients with echocardiographic evidence of ischemia at peak stress, 73 (83%) had evidence of ischemia at low stress. Change in wall motion score index from baseline to low stress represented 62% of the change noted from baseline to peak stress. A greater number of stenotic vessels were associated with a somewhat higher proportion of ischemic responses evident at low stress. The present study suggests that the maximal inotropic effects of arbutamine may occur at a dose lower than that required for maximal chronotropic effect. In the future, it may be possible to establish an infusion end point for arbutamine stress testing using a HR < 85% of the age-predicted maximum.

摘要

阿巴胺是一种新的、强效的、短效的合成儿茶酚胺,专门开发用作心脏应激剂。先前关于阿巴胺检测冠状动脉疾病准确性的报告依赖于心率(HR)增加,类似于运动峰值时所见。本研究旨在测试使用低于运动峰值相关心率的阿巴胺在超声心动图上诱发缺血性室壁运动异常的可能性。146例冠状动脉疾病患者接受了阿巴胺计算机化闭环应激测试;120例(82%)在基线、低应激(比基线高20次/分钟)和峰值应激(目标为年龄预测峰值心率的85%)时有足够的超声心动图图像用于分析。射血分数从基线时的59±10%增加到低应激时的72±12%,在峰值应激时保持稳定,为72±14%。在88例峰值应激时有超声心动图缺血证据的患者中,73例(83%)在低应激时有缺血证据。室壁运动评分指数从基线到低应激的变化占从基线到峰值应激变化的62%。更多的狭窄血管与低应激时明显更高比例的缺血反应相关。本研究表明,阿巴胺的最大正性肌力作用可能在低于最大变时性作用所需剂量时出现。未来,有可能使用低于年龄预测最大值85%的心率来确定阿巴胺应激测试的输注终点。

相似文献

1
Adequacy of low-stress arbutamine to provoke myocardial ischemia during echocardiography. International Arbutamine Study Group.超声心动图检查期间低应激剂量的阿巴美明诱发心肌缺血的充分性。国际阿巴美明研究组。
Am J Cardiol. 1995 Aug 1;76(4):259-62. doi: 10.1016/s0002-9149(99)80077-0.
2
Direct comparison of arbutamine and dobutamine stress testing with myocardial perfusion imaging and echocardiography in patients with coronary artery disease.冠心病患者中使用心肌灌注成像和超声心动图对阿巴胺和多巴酚丁胺负荷试验进行直接比较。
Am J Cardiol. 1997 Sep 15;80(6):716-20. doi: 10.1016/s0002-9149(97)00501-8.
3
Comparison of arbutamine and exercise echocardiography in diagnosing myocardial ischemia.比较阿巴胺与运动负荷超声心动图在诊断心肌缺血中的应用。
Am J Cardiol. 1997 Mar 15;79(6):713-6. doi: 10.1016/s0002-9149(96)00855-7.
4
Effects of dobutamine and arbutamine on regional myocardial function in a porcine model of myocardial ischemia.多巴酚丁胺和阿巴美丁对猪心肌缺血模型局部心肌功能的影响。
J Am Coll Cardiol. 1994 Feb;23(2):475-82. doi: 10.1016/0735-1097(94)90436-7.
5
Arbutamine echocardiography: efficacy and safety of a new pharmacologic stress agent to induce myocardial ischemia and detect coronary artery disease. The International Arbutamine Study Group.阿巴美明超声心动图检查:一种诱导心肌缺血和检测冠状动脉疾病的新型药物应激剂的疗效和安全性。国际阿巴美明研究小组。
J Am Coll Cardiol. 1995 Nov 1;26(5):1168-75. doi: 10.1016/0735-1097(95)00296-0.
6
A novel catecholamine, arbutamine, for a pharmacological cardiac stress agent.一种新型儿茶酚胺——阿巴美明,用作药理学心脏应激剂。
Cardiovasc Drugs Ther. 1996 Mar;10(1):31-8. doi: 10.1007/BF00051128.
7
Safety and efficacy of computerized closed-loop delivery of arbutamine: a new pharmacologic myocardial stress modality for the assessment of coronary artery disease. The European Arbutamine Study Group.阿巴胺计算机闭环给药的安全性和有效性:一种用于评估冠状动脉疾病的新型药理学心肌应激模式。欧洲阿巴胺研究小组。
J Am Soc Echocardiogr. 1995 Nov-Dec;8(6):854-63. doi: 10.1016/s0894-7317(05)80009-4.
8
Arbutamine vs. exercise stress testing in patients with coronary artery disease: evaluation by echocardiography and electrocardiography.冠心病患者中阿巴胺与运动应激试验的比较:通过超声心动图和心电图进行评估
Int J Cardiol. 1996 Nov 15;57(1):81-9. doi: 10.1016/s0167-5273(96)02765-9.
9
Safety and efficacy of closed-loop arbutamine stress echocardiography for detection of coronary artery disease. International Arbutamine Study Group.
Am J Cardiol. 1998 Jan 1;81(1):32-5. doi: 10.1016/s0002-9149(97)00800-x.
10
Arbutamine stress thallium-201 single-photon emission computed tomography using a computerized closed-loop delivery system. Multicenter trial for evaluation of safety and diagnostic accuracy. The International Arbutamine Study Group.使用计算机闭环给药系统的阿巴胺负荷铊-201单光子发射计算机断层扫描。评估安全性和诊断准确性的多中心试验。国际阿巴胺研究小组。
J Am Coll Cardiol. 1995 Nov 1;26(5):1159-67. doi: 10.1016/0735-1097(95)00298-7.

引用本文的文献

1
Patients' profiles in end stage coronary artery disease. Indications for treatment with transmyocardial laser revascularisation.
Herz. 1997 Aug;22(4):190-7. doi: 10.1007/BF03044577.
2
Comparison of arbutamine stress 99mTc-labeled sestamibi single-photon emission computed tomographic imaging and echocardiography for detection of the extent and severity of coronary artery disease and inducible ischemia.比较阿巴胺负荷试验99mTc标记的 sestamibi单光子发射计算机断层显像与超声心动图在检测冠状动脉疾病范围、严重程度及诱发心肌缺血方面的应用。
J Nucl Cardiol. 1997 May-Jun;4(3):211-6. doi: 10.1016/s1071-3581(97)90081-7.